Medical-affairs platforms (CME, MSL)

01Overview and value chain#

Markers EC: Pharmaceutical scientific-exchange compliance & promotion firewall | OECD: Bioeconomy policy & governance | Regulator: FDA (US), EFSA (EU)

Medical-affairs platforms are software systems purpose-built for pharmaceutical medical-affairs teams — the scientific-exchange function that must operate independently of commercial sales — covering medical science liaison (MSL) field engagement, medical-inquiry management, publication planning and continuing-medical-education content delivery. Veeva Vault Medical is the dominant unified platform, spanning medical-inquiry management, publications planning and MSL engagement in a single suite, with a dedicated Veeva MedComms product for medical-information case handling. TikaMobile in 2026 launched an “agentic AI” suite for medical-affairs operations, including a purpose-built medical-information platform (MedInfosys) alongside its established Tika MSL CRM. Mavens, now part of Komodo Health, runs Salesforce-based medical-affairs CRM implementations and was active at the 2026 ISMPP Europe meeting on medical-affairs and scientific-publications trends. PharmaForceIQ operates an HCP-compliant medical-affairs and MSL engagement platform alongside a unified commercial customer-engagement product, positioned on data security and partner integrations. Close-Up International, selected in 2026 by AGEPHA Pharma to power its US field force, provides AI-driven CRM technology for pharma field teams alongside a longer-running medical-education and congress-support business. IQVIA in 2026 unveiled IQVIA.ai, an NVIDIA-powered unified agentic-AI platform spanning its medical-affairs and broader life-sciences engagement tools, alongside country-specific deployments such as its Korea-market MediLens physician-engagement platform.

The key directions of medical-affairs platforms are:

MSL field CRM and engagement tracking: logging medical science liaison interactions with healthcare providers, tracking scientific-exchange topics discussed and territory coverage, kept structurally separate from sales CRM data.
Medical-inquiry management: routing and documenting unsolicited medical questions from healthcare providers to the correct medical-information specialist, with a full audit trail for regulatory review.
Publication planning and management: coordinating the drafting, internal review and journal-submission pipeline for clinical and scientific publications tied to a company’s products.
Agentic AI-assisted engagement: using AI agents to draft response content, summarize field interactions or recommend next engagement steps, an emerging 2026 direction across multiple vendors.

Sectoral value chain#

[MSL field engagement logging] ──> [Medical-inquiry intake & routing] ──> [Medical-information response drafting]
                                                                                        │
                                                                         (Compliance firewall: medical vs commercial data)
                                                                                        │
     [Regulatory audit trail] <──── [Publication planning & submission] <─── [Scientific-exchange documentation]

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
MSL field engagement	Logging medical science liaison visits, scientific-exchange topics and territory coverage in a dedicated CRM.	In: MSL field visit data, HCP contact records. Out: Structured engagement dataset.
Medical-inquiry intake	Capturing unsolicited medical questions from healthcare providers across channels (call center, web, field).	In: HCP inquiry, product/indication context. Out: Routed, categorized inquiry ticket.
Medical-information response	Drafting a compliant, medically accurate response to a routed inquiry, reviewed by a medical-information specialist.	In: Inquiry ticket, approved response library. Out: Documented response with audit trail.
Publication planning	Coordinating drafting, internal medical/legal review and journal-submission timelines for scientific publications.	In: Clinical/scientific data, author list. Out: Submitted or published manuscript record.
Compliance firewall enforcement	Structurally separating medical-affairs data and interactions from commercial/sales CRM data.	In: Platform access-control policy. Out: Auditable separation of medical vs commercial activity.
Regulatory audit trail	Maintaining a complete, timestamped record of medical-affairs activity for regulatory inspection.	In: All logged medical-affairs interactions. Out: Inspection-ready compliance record.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

Medical science liaison CRM: a customer-relationship-management system purpose-built to log MSL field interactions with healthcare providers, structurally partitioned from commercial sales CRM to preserve the medical/commercial firewall required by pharmaceutical compliance standards.
Agentic AI medical engagement: AI agents that draft medical-inquiry responses, summarize field-visit notes or recommend next scientific-exchange actions, an emerging 2026 capability layered onto established MSL and medical-information platforms.
Medical-inquiry management systems: structured intake, routing and documentation systems that route an unsolicited healthcare-provider question to the correct medical-information specialist and log the full response with an audit trail.

02US#

The United States hosts the most mature medical-affairs software ecosystem, anchored by platform incumbents and a wave of 2026 agentic-AI product launches.

Veeva’s unified medical-affairs suite, TikaMobile’s 2026 agentic AI launch, IQVIA’s NVIDIA-powered unified platform#

Veeva Vault Medical: the dominant unified platform spanning medical-inquiry management, publications planning and MSL engagement in a single suite, with a dedicated Veeva MedComms product for medical-information case handling.
TikaMobile: in 2026 launched a comprehensive agentic-AI suite for medical-affairs operations and a purpose-built medical-information platform (MedInfosys), alongside its established Tika MSL CRM product.
IQVIA: unveiled IQVIA.ai in 2026, an NVIDIA-powered unified agentic-AI platform spanning medical-affairs and broader life-sciences engagement tools, alongside country-specific deployments such as its Korea-market MediLens physician-engagement platform.

03CN#

China’s medical-affairs software market runs largely through the local operations of global platform vendors and domestic pharma internal systems rather than a dedicated China-headquartered medical-affairs platform vendor at the scale of the US firms profiled here.

Global vendors’ China-market deployments, no confirmed dedicated domestic vendor#

Global-vendor China deployments: IQVIA and other global life-sciences technology vendors maintain country-specific deployments across Asian markets (such as IQVIA’s Korea-market MediLens), suggesting a similar regional-deployment model likely extends into China, though a China-specific example could not be independently confirmed via a live 2026 source.
No confirmed dedicated domestic vendor: despite a live-source search, no China-headquartered medical-affairs-platform vendor comparable in scale to Veeva, TikaMobile or IQVIA could be confirmed; multinational pharma operating in China likely relies on the same global platforms used elsewhere, deployed locally.

04EU#

The European Union’s medical-affairs technology landscape includes both global-platform European operations and dedicated European field-engagement vendors.

Close-Up International’s AI-driven field CRM, ISMPP Europe as the regional medical-affairs venue#

Close-Up International: selected in 2026 by AGEPHA Pharma to power its US field force with AI-driven CRM technology, reflecting a longer-running medical-education and congress-support business now extending into AI-driven field-engagement software for pharma clients globally.
ISMPP Europe: the International Society for Medical Publication Professionals’ European meeting serves as a recurring venue where medical-affairs and scientific-publications trends are discussed, with vendors such as Mavens (Komodo Health) active participants in 2026.
Veeva and IQVIA European operations: both US-headquartered platform vendors maintain substantial European operations serving EU pharmaceutical companies’ medical-affairs functions under the same core product lines used in the US market.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Veeva Vault Medical	🇺🇸 USA	Unified medical-affairs suite, MedComms	Medical-inquiry, publications, MSL in one platform	commercial
TikaMobile	🇺🇸 USA	Tika MSL, MedInfosys	2026 agentic AI suite launch	commercial
Mavens	🇺🇸 USA	Salesforce-based medical-affairs CRM	ISMPP Europe 2026 active participant	operating
PharmaForceIQ	🇺🇸 USA	HCP-compliant medical-affairs platform	Unified field & brand engagement	commercial
Close-Up International	🇫🇷 France	AI-driven field CRM	AGEPHA Pharma 2026 US deployment	operating
IQVIA	🇺🇸 USA	IQVIA.ai unified agentic platform	NVIDIA-powered, country-specific deployments	commercial

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The medical-affairs technology stack combines structured CRM and inquiry-management systems with an emerging layer of agentic AI:

Medical science liaison CRM:
- A purpose-built CRM logs MSL field interactions — scientific-exchange topics discussed, territory coverage, follow-up actions — structurally partitioned from commercial sales CRM data to preserve the medical/commercial compliance firewall.
Agentic AI medical engagement:
- AI agents, launched across multiple vendors in 2026, draft medical-inquiry response content, summarize field-visit notes and recommend next scientific-exchange actions, layered onto established MSL and medical-information platforms rather than replacing them.
Medical-inquiry management systems:
- Structured intake and routing systems capture an unsolicited healthcare-provider question, route it to the correct medical-information specialist, and log the full response with a timestamped audit trail for regulatory inspection.

07Value chains and production pipelines#

Industrial pipeline for handling a medical inquiry through a compliant medical-affairs platform#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. HCP inquiry intake &    │ ───> │ 2. Categorization &        │
│    channel capture              │      │    routing                      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Medical/legal review     │ <─── │ 3. Response drafting from   │
│    of drafted response          │      │    approved content library     │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Response delivery &      │ ───> │ 6. Audit-trail logging &    │
│    HCP follow-up                │      │    compliance record            │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline for handling a medical inquiry through a compliant medical-affairs platform

Stage 1: HCP inquiry intake and channel capture

A healthcare provider submits an unsolicited medical question via call center, web form or field MSL visit, and the platform captures the inquiry with product and indication context.

Stage 2: Categorization and routing

The platform categorizes the inquiry by topic and product, then routes it to the correct medical-information specialist or therapeutic-area team.

Stage 3: Response drafting from approved content library

The specialist drafts a response using pre-approved medical content, increasingly assisted by an AI agent that suggests relevant approved-content passages.

Stage 4: Medical/legal review of drafted response

The drafted response undergoes internal medical and legal review to confirm it stays within approved, on-label scientific content before release.

Stage 5: Response delivery and HCP follow-up

The approved response is delivered to the healthcare provider, with any necessary follow-up scheduled through the MSL field-engagement workflow.

Stage 6: Audit-trail logging and compliance record

The full inquiry-to-response cycle is logged with timestamps, maintaining the auditable record regulatory inspectors review to confirm the medical/commercial compliance firewall held throughout.

Supplier	Region & tags
Veeva Vault Medical	US
TikaMobile	US
Mavens (Komodo Health)	US
PharmaForceIQ	US
Close-Up International	EU
IQVIA	US

AI Recommendation

Key directions:

MSL field CRM and engagement tracking — logging medical science liaison interactions, kept structurally separate from sales CRM.
Medical-inquiry management — routing unsolicited HCP questions to the correct medical-information specialist with a full audit trail.
Publication planning and management — coordinating drafting, review and journal-submission for scientific publications.
Agentic AI-assisted engagement — an emerging 2026 direction across multiple vendors, drafting response content and summarizing field interactions.

Regulatory:

The relevant pressure is not a licensing regime for the software itself.
It is the compliance requirement that medical-affairs (scientific-exchange) activity stay structurally separate from commercial sales — the “medical/commercial firewall” pharma companies must demonstrate to regulators.
FDA and EFSA oversight of promotional-versus-scientific content is what these platforms are built to keep auditable.

Companies not in table: a China-headquartered medical-affairs-platform vendor comparable in scale to the US and EU firms here could not be confirmed from a live 2026 source. The likely pattern is that multinational pharma in China deploys the same global platforms (Veeva, IQVIA) locally rather than using a dedicated domestic vendor, but this could not be independently verified.

Processing note: one candidate China-region firm was searched and returned no confirming live source, so the region is written qualitatively rather than tabled from general knowledge.